The Role of Vildagliptin in Treating Hypertension Through Modulating Serum VEGF in Diabetic Hypertensive Patients. [electronic resource]
Producer: 20200205Description: 254-261 p. digitalISSN:- 1940-4034
- Adult
- Antihypertensive Agents -- adverse effects
- Biomarkers -- blood
- Blood Pressure -- drug effects
- Captopril -- adverse effects
- Diabetes Mellitus, Type 2 -- blood
- Dipeptidyl-Peptidase IV Inhibitors -- adverse effects
- Egypt
- Female
- Glycated Hemoglobin -- metabolism
- Humans
- Hypertension -- blood
- Insulin Resistance
- Lipids -- blood
- Male
- Metformin -- adverse effects
- Middle Aged
- Prospective Studies
- Time Factors
- Treatment Outcome
- Vascular Endothelial Growth Factor A -- blood
- Vildagliptin -- adverse effects
No physical items for this record
Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.